Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir and Emtricitabine in HIV/HBV Co-Infection
NCT00127959Phase 4Completed
- Sponsor
- International Antiviral Therapy Evaluation Center
- Start
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tenofovir in human immunodeficiency virus infection (HIV) and hepatitis B (HBV) (2 arms), sponsored by International Antiviral Therapy Evaluation Center. Primary endpoint: HBV DNA suppression (AUC) at 48 weeks. Started Mar 2004; status: completed.
02
Drugs
tenofovir
03
Conditions
human immunodeficiency virus infection (HIV)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00127959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00127959.